COVID-19 long-haulers—even those who experienced mild cases—are at significantly increased risk for substantial declines in kidney function, such as organ damage and chronic and end-stage kidney disease (ESKD), according to a study today in the Journal of the American Society of Nephrology.
WHO releases new compendium of innovative health technologies for COVID-19 and other priority diseases.
A recent study in Antimicrobial Agents and Chemotherapy compared combination therapy consisting of a ß-lactam plus an aminoglycoside with ß-lactam monotherapy in hematological neutropenic patients with gram-negative bloodstream infections.